Results 51 to 60 of about 5,304 (170)
A guide to transcriptional cyclin‐dependent kinases in cancer
The FEBS Journal, EarlyView.Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone +2 morewiley +1 more sourceEvaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
CPT: Pharmacometrics & Systems Pharmacology, 2019 Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 to ...Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter, Nidal Al‐Huniti +7 moredoaj +1 more sourceAtrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Introduction
Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods
We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.Andrea Visentin, Enrica Antonia Martino, Alessandro Cellini, Francesco Angotzi, Annalisa Pitino, Andrea Duminuco, Ernesto Vigna, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Anna Maria Frustaci, Marcello Riva, Sara Pepe, Adalberto Ibatici, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Francesco Malaspina, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Fraticelli, Candida Vitale, Azzurra Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozella, Luigi Malandruccolo, Marzia Varettoni, Lucia Morello, Giuseppe Pietrantuono, Esmeralda Conte, Martina Cantelli, Roberta Murru, Daniele Caracciolo, Enrico Derenzini, Valentina Di Martina, Roberto Marasca, Maria Ilaria Del Principe, Amalia Figuera, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Nicola Amodio, Alessandro Allegra, Vittorio Del Fabro, Paolo Fiumara, Luca Scalise, Fabio Stagno, Giorgio Tona, Pellegrino Musto, Laura Caruso, Arcangelo Liso, Alessandra Tedeschi, Gianluca Gaidano, Francesca Romana Mauro, Giovanni Tripepi, Fortunato Morabito, Giuseppe Alberto Palumbo, Francesco Di Raimondo, Valter Gattei, Livio Trentin, Massimo Gentile +92 morewiley +1 more sourceA Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Introduction
BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.Steven M. Bair, John C. Byrd, Jonathan Gutman, Mitchell Phelps, Amy J. Johnson, Bita Fakhri, Kerry A. Rogers, Jennifer A. Woyach, Michael R. Grever, Manali Kamdar, Steven E. Coutre, Daniel A. Pollyea +11 morewiley +1 more sourceVenous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants
European Journal of Haematology, Volume 117, Issue 6, Page 1421-1441, December 2026.ABSTRACT
Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini +12 morewiley +1 more sourceEconomic Burden of Chronic Lymphocytic Leukaemia in Australia
European Journal of Haematology, Volume 117, Issue 6, Page 1541-1551, December 2026.ABSTRACT Background
The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods
A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...Lan Gao, Dieu Nguyen, Victoria White, Patricia M. Livingston, Chan Y. Cheah +4 morewiley +1 more sourceAge, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study
Cancer Medicine, Volume 15, Issue 11, November 2026.ABSTRACT Introduction
Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.Kevin Nasrinfar, Harrison Wildhaber, Rudolf Rohr, Gaëlle Rhyner Agocs, Urban Novak, Alessandra Curioni‐Fontecedro, Vérène Dougoud‐Chauvin +6 morewiley +1 more sourceAcalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia. We present results from ELEVATE-TN after a median follow-up of 74.5 months. Overall, 535 patients were randomized (acalabrutinib-obinutuzumab, Munir, Talha, Kamdar, Manali, Flinn, Ian W., Banerji, Versha, Byrd, John C, Suterwala, Batul T., Hughes, Marie, Munugalavadla, Veerendra, Wun, Chuan-Chuan, Herishanu, Yair, Woyach, Jennifer A., Jurczak, Wojciech, Patel, Krish, Fogliatto, Laura Maria, Woyach, Jennifer A, Ferrant, Emmanuelle, Janssens, Ann, Sharman, Jeff P., Flinn, Ian W, Walker, Patricia, Ferrajoli, Alessandra, Skarbnik, Alan, Follows, George, Miranda, Paulo, Wierda, William G, Sharman, Jeff P, Walewska, Renata, Suterwala, Batul T, Byrd, John C., Wierda, William G., Egyed, Miklos, Ghia, Paolo, Wachira, Catherine Wangui, Egyed M., Woyach J. A., Jurczak W., Byrd J. C., Walewska R., Fogliatto L. M., Suterwala B. T., Hughes M., Munugalavadla V., Herishanu Y., Ferrant E., Banerji V., Wierda W. G., Ghia P., Sharman J. P., Miranda P., Janssens A., Wun C. -C., Walker P., Ferrajoli A., Wachira C. W., Follows G., Skarbnik A., Flinn I. W., Munir T., Patel K., Kamdar M. +59 morecore +1 more sourceImpact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC
HemaSphere, Volume 10, Issue 11, November 2026.Abstract
The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...Candida Vitale, Thomas Chatzikonstantinou, Christina Papangelou, Francesca Perutelli, Maria Chiara Montalbano, Giulia Bondielli, Elia Boccellato, Salem Alshemmari, Francesco Angotzi, Miguel Arguello‐Tomas, Tomas Arpas, Sandra Bašić‐Kinda, Sotiria Besikli‐Dimou, Łukasz Bołkun, Tomasz Buczek, Aleksandra Butrym, Katherine Chapis, Sofia Chatzileontiadou, Rosa Collado, Raul Cordoba Mascuñano, Lorenzo De Paoli, Marina Deodato, Maria Dimou, David Donaldson, Joanna Drozd‐Sokołowska, Salem Elias, Andrea Ferrario, Alberto Fresa, Anna Maria Frustaci, Rocío García‐Serra, Ajay Gogia, Isabel González‐Gascón‐y‐Marín, Vasko Graklanov, Maria Hryniewiecka, Zhu Huayuan, Elzbieta Iskierka‐Jażdżewska, Paula Jablonowska‐Babij, Ozren Jaksic, Elzbieta Kalicińska, Maria Kislova, Maya Koren‐Michowitz, Epameinondas Koumpis, Zuzana Kubová, Jorge Labrador, Pietro Lauzzana, Shai Levi, Francesca Martini, Mariia Mikhaleva, Eva Minga, Riccardo Moia, Elżbieta Morawiec‐Szymonik, Marta Morawska, Femke V. M. Mulder, Roberta Murru, Jacopo Olivieri, Ewa Paszkiewicz‐Kozik, Lata Rani, Josep Maria Roncero, Wojciech Salamon, Alessandro Sanna, Lydia Scarfò, Tereza Shokralla, Martin Šimkovič, Matevž Škerget, Emil Spasov, Antigoni Tranidou, Jagoda Tryc‐Szponder, Marzia Varettoni, Andrea Visentin, George Vrachiolias, David Waddell, Ewa Wasik‐Szczepanek, Kamil Wdowiak, Mateusz Wilk, Kamil Wiśniewski, Magdalena Witkowska, Mohamed Yassin, Seyma Yıldız, Klaudia Zielonka, Nil Albiol, Jennifer R. Brown, Benedetto Bruno, Mark Catherwood, Anastasia Chatzidimitriou, Michael Doubek, Gianluca Gaidano, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Krzysztof Jamroziak, Ioannis Kotsianidis, Luca Laurenti, Eugene Nikitin, Maria Papaioannou, Tomáš Papajik, Martin Špaček, Niki Stavroyianni, Josephine M. I. Vos, Tomasz Wróbel, Münci Yağcı, Arnon P. Kater, Matthew Davids, Petra Langerbeins, Kostas Stamatopoulos, Paolo Ghia, Marta Coscia +106 morewiley +1 more source